NanoString Technologies, Inc. develops, manufactures, and sells technology for scientific and clinical information in the fields of genomics and proteomics in the Americas, Europe, the Middle East, and the Asia Pacific. The company offers the nCounter Analysis System, an automated, multi-application, digital detection, and counting system.
It provides nCounter Pro and FLEX systems that include the Prep Station, an automated liquid handling component that processes and prepares samples for data collection; and the nCounter Digital Analyzer, which collects data from samples by taking images of the immobilized fluorescent reporters in the sample cartridge and processing the data into output files.
The company also offers the nCounter SPRINT Profiler, an instrument that provides liquid handling steps and digital analysis through the use of a microfluidic cartridge; and nSolver Analysis Software, a data analysis program that enables researchers to check, normalize, and analyze their data.
In addition, it provides custom CodeSets; panels with oncology, immunology and infectious disease, and neuroscience applications. Further, the company offers Master Kits, cartridges, ancillary reagents, tips, and reagent plates to set up and process samples in instruments; and Prosigna in vitro diagnostic kits.
The company is also developing the GeoMx DSP system to enable the field of spatial biology. It has collaborations with Lam Research Corporation for the development of an NGS sequencing platform and related assays; and with the Parker Institute for Cancer Immunotherapy to develop CAR-T regimens that enhance patient outcomes for various types of cancer. Additionally, it collaborates with Stanford Medicine, Acrobat Genomics, and Illumina Accelerator to discover new drug targets for gene editing-based therapeutics.
NanoString Technologies, Inc. was incorporated in 2003 and is headquartered in Seattle, Washington. On February 4, 2024, NanoString Technologies, Inc., along with its affiliates, filed a voluntary petition for reorganization under Chapter 11 in the U.S. Bank.
